摘要
目的 探讨康艾注射液联合索拉非尼治疗晚期肾癌患者的临床疗效.方法 将50例晚期肾癌患者根据治疗方式的不同分为索拉非尼组(n=24)和康艾组(n=26).索拉非尼组患者采取索拉非尼治疗,康艾组患者在索拉非尼组的基础上联合康艾注射液治疗.比较两组患者疗效、免疫功能指标(CD3+、CD4+、CD8+、CD4+/CD8+)、不良反应发生情况及生活质量.结果 康艾组患者总有效率高于索拉非尼组,差异有统计学意义(P﹤0.05).治疗后,两组患者CD3+、CD4+水平及CD4+/CD8+均较治疗前升高,CD8+水平均较治疗前降低,且康艾组患者CD3+、CD4+水平及CD4+/CD8+均高于索拉非尼组,CD8+水平低于索拉非尼组,差异均有统计学意义(P﹤0.05).治疗后,两组患者躯体功能、认知功能、社会功能、情绪功能、角色功能评分均较治疗前升高,且康艾组患者躯体功能、认知功能、社会功能、情绪功能、角色功能评分均高于索拉非尼组,差异均有统计学意义(P﹤0.05).两组患者不良反应总发生率比较,差异无统计学意义(P﹥0.05).结论 康艾注射液联合索拉非尼可提高晚期肾癌患者临床疗效,改善患者免疫功能及生活质量,且不增加不良反应.
Abstract
Objective To investigate the clinical efficacy of Kang'ai injection combined with sorafenib in the treat-ment of advanced renal carcinoma.Method A total of 50 patients with advanced renal carcinoma were divided into sorafenib group(n=24)and Kang'ai group(n=26)according to different treatment methods.Sorafenib group was treated with sorafenib,and Kang'ai group was treated with Kang'ai injection on the basis of sorafenib group.The efficacy,im-mune function indexes(CD3+,CD4+,CD8+,CD4+/CD8+),adverse reactions and quality of life were compared between the two groups.Result The total effective rate of Kang'ai group was higher than that of sorafenib group,the difference was statistically significant(P<0.05).After treatment,the levels of CD3+,CD4+ and CD4+/CD8+ in both groups were higher than those before treatment,while the levels of CD8+ were lower than those before treatment,and the levels of CD3+,CD4+ and CD4+/CD8+ in Kang'ai group were higher than those in sorafenib group,while the level of CD8+ was lower than that in sorafenib group,the differences were statistically significant(P<0.05).After treatment,the scores of physical function,cognitive function,social function,emotional function and role function in the two groups were higher than those before treatment,and the scores of physical function,cognitive function,social function,emotional function and role function in Kang'ai group were higher than those in sorafenib group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Kang'ai injection combined with sorafenib can improve the clinical efficacy,immune function and quality of life of patients with advanced renal carcinoma without increasing adverse reactions.
维普
万方数据